Grants for State governments - Health

This funding opportunity supports U.S. institutions in providing research education and mentorship for recent graduates from diverse backgrounds to prepare them for neuroscience doctoral programs.

The purpose of this program is to (a) promote full integration and collaboration in clinical practices between physical and behavioral health care; (b) support the improvement of integrated care models for physical and behavioral health care to improve overall wellness and physical health status; and (c) promote the implementation and improvement of bidirectional integrated care services, including evidence-based or evidence-informed screening, assessment, diagnosis, prevention, treatment, and recovery services for mental and substance use disorders, and co-occurring physical health conditions and chronic diseases through integrated care. State recipients are expected to partner with qualified community programs, health centers, rural health clinics, or Federally Qualified Health Centers to develop and implement an integration program plan. With this program, SAMHSA aims to improve the health outcomes for persons with behavioral health conditions by supporting the adoption and improvement of integrated care models for behavioral and primary physical health.

This funding opportunity provides financial support to nonprofit organizations, government entities, and educational institutions in Ohio to enhance and sustain trauma-informed care initiatives across six designated regions.

This funding opportunity supports collaborations between academic institutions and industry to develop innovative technologies that improve disease diagnosis, treatment, and management, particularly for underserved populations.

This funding opportunity supports research into how certain diabetes medications may influence cancer risk, encouraging studies that explore the underlying biological mechanisms involved.

This funding opportunity is designed for healthcare institutions and organizations in the U.S. to improve the management and outcomes of migraine patients in emergency departments.

This funding opportunity provides financial support to organizations working to combat domestic violence, dating violence, sexual assault, and stalking in rural communities across the U.S.

This grant provides funding for innovative research using invasive brain recording and stimulation techniques in humans to improve understanding of the neural circuits involved in mental health disorders.

The purpose of the NINDS Research Program Award (RPA) is to provide longer-term support, and increased freedom and flexibility, to Program Directors (PDs)/Principal Investigators (PIs), to allow them to redirect their time away from the administrative burden of writing and managing multiple grant applications and towards engaging in the lab. This RPA affords investigators at most career stages the opportunity to advance their long-term research goals, rigorously explore exciting research opportunities, and mentor students and postdoctorates, which support and align with the mission of NINDS. RPAs will support the overall research programs of NINDS-funded investigators for up to 8 years, at a level commensurate with a PD/PIs recent NINDS support (Part 2, Section II). This funding stability will provide eligible investigators increased security, allowing them to undertake research projects that require a longer timeframe or to embark upon research that breaks new ground. Research activities outside of the NINDS mission, or traditionally supported by another NIH Institute or Center, will not be considered through this program. Benefits of the RPA include: A more stable funding environment, facilitating the pursuit of longer-term research goals; Flexible funding, enabling investigators to pursue research opportunities as they arise, not tied to specific aims; Reduced time spent writing grant applications and managing multiple grant awards, allowing investigators to spend more time conducting and overseeing research; More time for PDs/PIs to mentor and foster a diverse workforce in their laboratories. NINDS is committed to enhancing the diversity and inclusiveness of the neuroscience workforce. A diverse NIH-supported scientific workforce, including individuals from underrepresented groups, fosters scientific innovation, enhances global competitiveness, contributes to robust learning environments, and improves the quality of the research. See the Notice of NIH

This funding opportunity supports researchers conducting observational studies to improve understanding and treatment of musculoskeletal, rheumatic, and skin diseases, with a focus on patient outcomes and disease progression.

The Centers for Medicare Medicaid Services (CMS), through its Center for Medicare and Medicaid Innovation, is soliciting applications for the Transforming Maternal Health (TMaH) Model. This is a voluntary, 10-year service delivery and payment model designed to improve maternal health care outcomes for people enrolled in Medicaid and the Children's Health Insurance Program (CHIP). The TMaH Model will test whether targeted technical (TA) assistance, coupled with payment and delivery system reforms, can drive a whole-person care-delivery approach to pregnancy, childbirth, and postpartum care while reducing Medicaid and CHIP program expenditures. CMS will select up to 15 state Medicaid agencies (SMAs or Recipients) to participate in the TMaH Model. Up to $17 million dollars in Cooperative Agreement funding will be available to each selected Recipient over the course of the 10-year period of performance for a total of up to $255M investment. CMS will evaluate the following: the TMaH Models impact on rates of lower c-risk cesarean section (c-section), severe maternal morbidity (SMM), incidence of low birthweight infants, changes in experience of care for pregnant and birthing people, and changes in Medicaid and CHIP program expenditures. The TMaH Model aims to improve maternal and child health outcomes while reducing Medicaid and CHIP program expenditures for maternal care through reduced spending on high-cost procedures such as c-sections for low-risk beneficiaries.

This funding opportunity is designed to establish a center that will coordinate and advance research on whole person health by integrating diverse biomedical knowledge and fostering collaboration among researchers.

This funding opportunity supports researchers with active NCI U01 awards who want to integrate innovative cancer research technologies to improve their studies and advance cancer prevention, detection, diagnosis, and treatment.

This funding opportunity supports research to uncover genetic factors related to mental disorders in diverse populations, particularly those of non-European ancestry, while promoting community engagement and career development for early-career researchers.

Allergic reactions to drugs and vaccines are a serious public health concern. For the purpose of this notice of funding opportunity (NOFO), allergic reactions include not only IgE-mediated reactions, but other immune-mediated and largely unpredictable drug and vaccine reactions. Based on data from 2013-2014, each year in the United States there are an estimated 200,000 emergency department visits for adverse events related to antibiotics. In children 5 or younger, antibiotics cause more than half (56%) of estimated emergency department visits for adverse drug events and 82% of these visits are due to allergic reactions. Allergic reactions to antibiotics include immediate life-threatening reactions such as anaphylaxis, severe cutaneous reactions including Toxic Epidermal Necrolysis and Drug Reaction with Eosinophilia and Systemic Symptoms, and less severe reactions that still limit further use of the drugs. A label of antibiotic allergy leads to the use of alternative, frequently more expensive antibiotics, often with lower efficacy, which may contribute to antibiotic resistance as well as increased mortality and morbidity in hospitalized patients. While allergic reactions to vaccines are less common, the inability to receive a vaccine due to an allergy is problematic to the individual, and the perceived risk of allergic reactions to vaccines contributes to vaccine hesitancy creating a public health issue. Objectives The objective of this NOFO is to solicit innovative projects to study the mechanisms and management of vaccine or antibiotic drug allergy (research on allergic responses to anti-viral, anti-fungal and anti-parasitic drugs will also be considered). The scope of research into antibiotic or vaccine allergic reactions includes, but is not limited to, the following: IgE-mediated and other mechanisms of immediate allergic antibiotic or vaccine reactions Non-IgE-mediated urticarial reactions to antibiotics or vaccines Delayed-type hypersensitivity reactions to antibiotics or vaccines Severe cutaneous adverse antibiotic or vaccine reactions Biomarkers to identify people at risk for reaction or to confirm reactions to specific antibiotics or vaccines Host factors that may predispose to allergic reactions including, but not limited to, host microbiome, genetics, or inflammatory conditions Mechanisms by which specific infections may increase the risk of an allergic reaction to an antibiotic or vaccine Immunomodulatory approaches to treating or preventing immunologic adverse antibiotic or vaccine reactions A secondary objective of this NOFO is to expand the number of investigators working in the field of vaccine and antibiotic drug allergy. Early-stage investigators are encouraged to apply. UG3/UH3 phase transition and Milestones This funding opportunity is designed as a two-stage cooperative agreement in which Project Scientists from NIAID will work with the investigative team. It will support projects that are organized into a two-year UG3 phase followed by a three-year UH3 phase. The UG3 phase may include pilot, observational, or hypothesis-generating high-risk projects. Preliminary data may be helpful but are not required. The use of electronic health records to identify potential participants for mechanistic studies is allowed. The use of human samples such as those related to clinically indicated and routinely used interventions or tests is encouraged. The UG3 must include milestones to determine the success of the project at the end of this phase. Milestones may be negotiated or re-negotiated after award as this program includes the flexibility to quickly revise milestones and/or aims within the scope of the original peer-reviewed application. Following the completion of the UG3 phase, NIAID staff will review the progress made and make the determination on whether the project will continue to the UH3 phase. NIAID support for the UH3 is contingent upon progress made during the UG3 phase, meeting the milestones, programmatic priorities, the original UG3/UH3 peer review recommendations, and the availability of funds. Some projects might not transition from the UG3 to the UH3 phase. Projects supported by the UH3 phase are required to be hypothesis driven, mechanistic, and extend the work initiated by the UG3 phase. Program Director/Principal Investigator (PD/PI) Meeting Attendance A kick-off meeting and annual meetings will be organized by NIAID to facilitate interactions among recipients to share approaches, data, and methods, with the aim of developing a cadre of dedicated researchers to conduct antibiotic and vaccine allergy and advance mechanistic research. These meetings will convene yearly in the Rockville, Maryland area and will be held in person, though a virtual component will be available to allow broader participation from laboratory members. The PD/PI from each award is expected to attend the kickoff meeting and annual meetings in person. Applications that propose the following topics will be considered non-responsive and will not be reviewed: Adverse drug reactions that are predictable and/or related to pharmacologic properties of the drug such as toxicity or overdose Investigation into drugs that are not antibiotics or vaccines (however research on anti-viral, anti-fungal and anti-parasitic drugs is allowed) Investigations into Guillain-Barré Syndrome or drug-induced autoimmune reactions Investigations of central nervous system and other neurologic adverse responses Investigations into the pathogens rather than host allergic responses to the antibiotics or vaccines Applications that do not propose mechanistic research in the UH3 phase Vaccines that are administered via a route that is not the same route of administration as approved by the FDA Vaccines that are used as an immunotherapeutic (e.g. allergen immunotherapy) HIV/AIDS research

This funding opportunity supports collaborative research teams of diverse experts to tackle ambitious challenges in dental, oral, and craniofacial science, focusing on innovative solutions like non-opioid pain therapies and health disparity-reducing technologies.

This funding opportunity supports researchers in developing innovative tools to measure human behavior and synchronize these measurements with brain activity, aiming to advance our understanding of brain-behavior relationships and improve interventions for neurobehavioral conditions.

This funding opportunity supports researchers in analyzing existing oral health data or developing new statistical methods to improve data analysis, with a focus on establishing causal relationships rather than just identifying correlations.

The "Access and Manipulation of Brain Cell Subtypes Implicated in Aging and AD/ADRD" grant aims to fund innovative research strategies that use advanced tools to target and manipulate specific brain cells affected by aging, Alzheimer's Disease, and related dementias, in order to better understand these conditions and their impact on brain function.

This funding opportunity supports innovative research on how communication between mitochondria and the nucleus affects Alzheimer’s Disease and related dementias, inviting applications from universities, nonprofits, and other organizations.